Servier has been 'named and shamed' in the medical press for breaching the Association of the British Pharmaceutical Industry's ABPI Code of the Practice after it failed to disclose several clinical study results in a suitable timeframe. Clinical Trial Transparency: an assessment of the disclosure results of company-sponsored trials associated with new medicines approved recently in Europe was co-authored by Dr Bina Rawal, director of research, medical and innovation at the ABPI , and pharma consultant Bryan Deane. On reading the journal article an anonymous member of the public complained to the PMCPA, saying that some companies mentioned in the report had not disclosed clinical trial results in line with the ABPI's Code of Practice. One of these was Servier for clinical trials involving its antidepressant Valdoxan agomelatine — two of which were published later than they should have been.
|Published (Last):||1 December 2004|
|PDF File Size:||13.49 Mb|
|ePub File Size:||18.18 Mb|
|Price:||Free* [*Free Regsitration Required]|
Pharma insight on digital marketing, social media, mobile apps, online video, websites and interactive healthcare tools. A website produced by Shire to provide UK patients and healthcare professionals with information on its Gaucher disease drug Vpriv has fallen foul of pharma industry rules. The site, www. But a complaint that Shire had not followed digital marketing rules, in the process making information on prescription-only medicines available online to the general public, was thrown out.
In the US such sites are synonymous with direct-to-consumer DTC advertising, something strictly prohibited in the UK and the rest of Europe, so UK versions of these sites need clearly differentiated sections for their two different audiences. Genzyme markets its own Gaucher disease drug Cerezyme which, like Vpriv, is an enzyme replacement therapy. The rule breaches, which came under clauses 7. Digital inspiration for pharma on mobile, social media, strategy, best practice, regulations and more.
From: Marketing. Wisepress is a medical bookseller promoting and selling books worldwide, both online and via the European medical conferences that Please login to the form below. I have forgotten my password. Advanced search. Trending Interview with Novo Nordisk's Ludovic Helfgott Five pharma leaders to watch in Tackling antimicrobial resistance The changing nature of approvals. Digital intelligence blog Pharma insight on digital marketing, social media, mobile apps, online video, websites and interactive healthcare tools.
Shire website breaches UK pharma code But healthcare professional section of vpriv. PMHub Add my company Any category Advertising Branding Clinical research Conferences meetings events Creative and design Digital communications Homecare Industry associations IT solutions Management consultancies Manufacturing packaging logistics Market access Market research Marketing consultancies Media planning and buying Medical communications Medical education Patient support and adherence Pharmacy Print services Policy and government affairs Public relations Publishers Recruitment and career development Regulatory affairs Research and development Sales Training Translation services Wisepress Wisepress is a medical bookseller promoting and selling books worldwide, both online and via the European medical conferences that PMEA Winners in pictures.
Digital intelligence blog
Among other changes, the Code will be updated to reflect the end of disclosure of aggregate payments to healthcare professionals. Changes are also needed to take account of the end of the transition from the aggregate disclosure Code of certain payments. In the ABPI will switch to a new system where companies will have to reveal individual payments made to healthcare professionals. From 30 June, companies will be reporting payments made to individual, named, healthcare professionals, starting with payments made during , on a searchable database managed by the ABPI. The new system will include payments for four categories of activity: registration fees for meetings and events, travel and accommodation, fees for consultancy and services, and expenses for consultancy and services.
PMCPA updates e-learning module for health professionals and quick guides to the Code
Pharma insight on digital marketing, social media, mobile apps, online video, websites and interactive healthcare tools. There are no plans to produce more social media guidelines for UK pharma, but that shouldn't stop companies from using the technology. It is now in the hands of industry to push the boundaries and scope of digital media, while still working within the Code of Practice. To date the digital media working group has looked at UK pharma's use of Twitter, Facebook and other social media channels, and discussions have also focused on how case studies could be used to illustrate different ways of using social media. But at its recent second meeting it was decided that producing new guidance would only increase confusion levels, rather than address the needs of pharma companies that are at varying levels of progress. Instead, the ABPI will ask its member companies to look again at the existing guidance and then say where their needs lie and what else they need in the way of support.